01—Abstract
Summary
Summary of the 8-K filed January 27, 2025. Cited figures are marked; the original filing is the authoritative source.
On January 24, 2025, Neurocrine Biosciences, Inc. entered into an Amended and Restated Exclusive License Agreement with Takeda Pharmaceutical Company Limited, which amends and restates in its entirety the Exclusive License Agreement dated June 12, 2020.
The amendment converts the arrangement for osavampator (NBI-1065845 / TAK-653), a potential first-in-class AMPA positive allosteric modulator in development for patients with inadequate response to treatment of major depressive disorder, from a shared operating profit and loss structure to a royalty-bearing license. Neurocrine will hold exclusive worldwide development and commercialization rights to osavampator for all indications, excluding Japan, where Takeda will reacquire exclusive rights. Each party will bear development costs in its own territory and is eligible to receive royalties on the other party's net sales in that territory.
Takeda is now eligible for development and commercial milestones, as contemplated in the original agreement. The filing also states that the company previously terminated the DAAO inhibitors under the original agreement, including luvadaxistat, and the GPR139 agonists, including NBI-1070770 (listed as NBI-1065846 in the filing). Neurocrine stated that, upon successful development and commercialization of osavampator, it expects tiered royalties payable to Takeda in the mid-to-upper teens in the United States and low double-digits outside the United States, on a blended basis as a percentage of net sales.
The company would also be entitled to royalties from Takeda on net sales in Japan. Neurocrine's CEO, Kyle Gano, Ph.D., said the company had completed its End-of-Phase 2 meeting with the FDA for osavampator and expects to begin the Phase 3 program in the first half of 2025.
The full agreement will be filed as an exhibit to the company's Form 10-Q for the period ending March 31, 2025, with confidential terms redacted. The Regulation FD press release announcing the agreement is furnished as Exhibit 99.1.
02—Key points
Key Highlights
- Neurocrine obtains exclusive worldwide development and commercialization rights to osavampator for all indications, excluding Japan.
- Takeda reacquires exclusive rights to osavampator in Japan.
- The economic structure changes from shared operating profits and losses to a royalty-bearing license, with each party bearing development costs in its own territory.
- Neurocrine expects tiered royalties payable to Takeda in the mid-to-upper teens in the United States and low double-digits outside the United States, on a blended basis as a percentage of net sales, upon successful commercialization.
- Neurocrine would be entitled to royalties from Takeda on net sales in Japan.
- Takeda is now eligible for development and commercial milestones.
- Neurocrine plans to begin the Phase 3 program for osavampator in the first half of 2025, following a completed End-of-Phase 2 meeting with the FDA.
03—Questions
Frequently Asked Questions
What changed in the Neurocrine and Takeda osavampator agreement?
The Amended and Restated Exclusive License Agreement converts the osavampator arrangement from sharing operating profits and losses into a royalty-bearing license. Neurocrine retains worldwide rights excluding Japan, and Takeda reacquires rights in Japan.
What royalties will Neurocrine pay Takeda?
Upon successful development and commercialization of osavampator, Neurocrine expects tiered royalties payable to Takeda in the mid-to-upper teens in the United States and low double-digits outside the United States, on a blended basis as a percentage of net sales.
Does Neurocrine receive any economic benefit from Japan?
Yes. The company states it would be entitled to receive royalties from Takeda on net sales of osavampator in Japan.
What are the next development steps for osavampator?
Neurocrine said it completed an End-of-Phase 2 meeting with the FDA and expects to begin the Phase 3 program in the first half of 2025. The osavampator program is in development for patients with inadequate response to treatment of major depressive disorder.
Where can investors find the full terms of the agreement?
The company states the full Restated License Agreement will be filed as an exhibit to its Quarterly Report on Form 10-Q for the period ending March 31, 2025, with confidential terms redacted.
04—Continue